The lidocaine metabolite N-ethylglycine has antinociceptive effects in experimental inflammatory and neuropathic pain by Werdehausen, R et al.
Research Paper
The lidocaine metabolite N-ethylglycine has
antinociceptive effects in experimental
inflammatory and neuropathic pain
Robert Werdehausena,b,*, Sebastian Mittnachtc, Lucy A. Beeb, Michael S. Minettb, Anja Armbrusterc, Inge Bauera,
John N. Woodb, Henning Hermannsa,d, Volker Eulenburgc
Abstract
Glycine transporter 1 (GlyT1) plays a crucial role in regulating extracellular glycine concentrations and might thereby constitute a new
drug target for the modulation of glycinergic inhibition in pain signaling. Consistent with this view, inhibition of GlyT1 has been found to
induce antinociceptive effects in various animal pain models. We have shown previously that the lidocaine metabolite N-ethylglycine
(EG) reduces GlyT1-dependent glycine uptake by functioning as an artificial substrate for this transporter. Here, we show that EG is
specific for GlyT1 and that in rodent models of inflammatory and neuropathic pain, systemic treatment with EG results in an efficient
amelioration of hyperalgesia and allodyniawithout affecting acute pain. Therewasnoeffect onmotor coordination or the development of
inflammatory edema. No adverse neurological effects were observed after repeated high-dose application of EG. EG concentrations
both in blood and spinal fluid correlated with an increase of glycine concentration in spinal fluid. The time courses of the EG and glycine
concentrations correspondedwell with the antinociceptive effect. Additionally, we found that EG reduced the increase in neuronal firing
of wide-dynamic-range neurons caused by inflammatory pain induction. These findings suggest that systemically applied lidocaine
exerts antihyperalgesic effects through its metabolite EG in vivo, by enhancing spinal inhibition of pain processing through GlyT1
modulation and subsequent increase of glycine concentrations at glycinergic inhibitory synapses. EG and other substrates of GlyT1,
therefore, may be a useful therapeutic agent in chronic pain states involving spinal disinhibition.
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1. Introduction
Persistent inflammatory stimuli or lesions as well as diseases
affecting the somatosensory system can lead to distinct and long-
lasting alterations in the nociceptive system that result in
spontaneous pain and exaggerated responses to innocuous
and noxious stimuli. Chronic pain that results from these
maladaptive responses loses its warning function and is
considered an autonomous disease state.11 Given that roughly
20% of the population suffer from chronic pain,7,22 there is
a crucial need for further unraveling the mechanisms of chronic
pain states in order to develop new mechanism-oriented
treatment strategies.4
The development and maintenance of chronic pain involves
profound changes in the neuronal processing of sensory
information. In addition to adaptive changes within the peripheral
nervous system, there are numerous studies suggesting that
pathological alterations in the somatoafferent nervous system in
chronic pain conditions result in an imbalance of excitatory and
inhibitory spinal neurotransmission predominantly in spinal
cord.44 Particularly, the loss of GABAergic and glycinergic
synaptic neurotransmission has gained increased interest, since
it is believed that a pharmacological restoration of physiological
inhibition in the spinal cord might represent a future therapeutic
approach.51 Here, targeting of GABAergic neurotransmission
has largely failed, in part due to an ubiquitary abundance of
GABAA receptors,
51 although a1-sparing GABAA receptor
agonists have yet to be tested in patients.30 Although there are
studies demonstrating that the analgesic effects of cannabinoids
result from a facilitation of a3 containing glycine receptors
(GlyRs),48 to date, there have been no specific GlyR facilitators/
agonists available with suitable pharmacological profiles.
Current recommendations for the management of patients
suffering from neuropathic pain include the treatment with tricyclic
antidepressants, dual reuptake inhibitors for serotonin and
norepinephrine, calcium channel a2d ligands, opioids, and topical
application of lidocaine or capsaicin.2,3,14 In addition to significant
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adverse effects, all known pharmacological approaches typically
show only limited efficacy in the majority of patients.18,45
Systemic long-term application of lidocaine is currently
recommended as a promising approach to treat neuropathic
pain.9 The principle mode of action of lidocaine is blockade of
voltage-gated sodium channels.49 Considering the low concen-
trations of systemically delivered lidocaine that have proven to be
effective in neuropathic pain and its low affinity to voltage-gated
sodium channels, this mechanism seems unlikely to be able to
explain the antinociceptive effects.12,43 Previously, we have
shown that a lidocaine metabolite, N-ethylglycine (EG), is an
alternative substrate of the glycine transporter GlyT1, suggesting
that EG and not lidocaine itself is responsible for some of the
beneficial effects of lidocaine in the treatment of neuropathic
pain.46 This hypothesis is supported by studies showing that
GlyT1 inhibitors efficiently ameliorated hyperalgesia and allodynia
in animal models of chronic pain.8,35,42
Here, we show that the lidocaine metabolite EG is specific for
GlyT1 and that it ameliorates hyperalgesia and allodynia in animal
models for chronic pain. We observed no adverse effects, in
contrast to the application of high-affinity GlyT1 antagonists like
ALX5407 or the parental substance lidocaine. Taken together,
our findings demonstrate that the use of GlyT1 substrates might
be a good alternative for treatment of chronic pain syndromes.
2. Materials and methods
Unless stated otherwise, all reagents were purchased from
Sigma-Aldrich (St. Louis, MO). All animal experiments were
performed in accordance with animal welfare regulations and
approved by local authorities. All animals were housed in
a controlled environment (21˚C 6 1˚C; humidity 60%; lights on
from 7 AM to 7 PM; food and water available ad libitum).
2.1. Electrophysiological recordings from Xenopus
laevis oocytes
Oocytes, isolated fromXenopus laevis, were injectedwith 1 to 20ng
of the indicated mouse complementary RNA (cRNA), or left
noninjected. For coexpression of GlyR b subunits with the
respective GlyR a subunit, a 10-fold excess of GlyR b cRNA was
injected 24 hours before injecting the respective GlyR a cRNA to
ensure that the majority of receptors formed are indeed GlyR
heteropentamers. The oocytes were incubated for 2 to 4 days at
18˚C in ND96medium (containing [in mM] NaCl 96, KCl 2, MgCl2 1,
CaCl2 1, HEPES/NaOH 5, and 50 mg/mL gentamycin; pH 7.4) to
ensure a sufficient expression of the corresponding protein. Ion
channel or transporter-mediated currents were analyzed by 2-
electrode voltage-clamp recordings. All recordings were performed
using a Turbo TEC-03X amplifier and CellWorks (V3.7) data
acquisition software (all fromNPI Electronics, Go¨ttingen, Germany).
For the recordings, themembrane potential was held constant at2
50 mV. Typically, substance applications of indicated increasing
concentrations were performed for 10 to 30 seconds, followed by
a washout step with ND96 superfusion solution (containing [in mM]
NaCl 96, KCl 2, MgCl2 1, HEPES/NaOH 5, pH 7.4), or for
measurements of N-methyl-D-aspartate receptor (NMDAR)–
mediated currents ND96 (-Mg) (containing [in mM] NaCl 96; KCl,
2, CaCl2 0.1, HEPES/NaOH 5, pH 7.4) for at least 30 seconds. The
measurements were repeated in at least 3 different populations of X
laevis oocytes. Current amplitudes are, if not indicated otherwise,
presented as relative substance-induced currents (mean 6 SEM,
n5 4-6), with the respectivemaximal glycine-induced current being
defined as 100%.
2.2. Animal models of pain and treatment experiments
Inflammatory pain was induced by subcutaneous injection of
20 mL complete Freund’s adjuvant (CFA) (1 mg/mL Mycobacte-
rium tuberculosis) solution into the plantar side of the left hind paw
in adult male C57BL/6Jmice.41 Test drugswere applied 72 hours
after injection of CFA and development of reduced withdrawal
thresholds in response to mechanical stimulation indicative for
mechanical allodynia. To investigate the effect of EG on wide-
dynamic-range (WDR) neuron responses in inflammatory pain,
carrageenan (1%, 20 mL) was injected into the left hind paw of
adult male Wistar rats. When neuronal hyperexcitability had
developed 3 hours after the injection of carrageenan, EG at
indicated concentrations was applied into the subarachnoid
space.
Chronic neuropathic pain was induced through the chronic
constriction injury (CCI) model in adult male C57BL/6J mice,6
consisting of 3 loose ligatures around the left sciatic nerve, which
were performed under general anesthesia using isoflurane
(Baxter, Deerfield, IL). Test drugs were applied 72 hours after
surgery. All drugs were injected subcutaneously into the loose
skin over the neck. To investigate possible toxic effects of the test
substances, the animals were thoroughly observed after high-
dose treatment of the respective substance for signs of
neurotoxicity (irregular movements, signs of distress) until 360
minutes after subcutaneous injection.
2.3. Behavioral tests
An experimenter who was blinded to the randomized treatment
group assignment performed all behavioral tests. Touch percep-
tion thresholds were measured using the up–down method for
obtaining the 50% threshold using von Frey hairs.10 Behavioral
response to heat was measured using the Hargreaves method23
(Plantar Test Apparatus; Ugo Basile, Varese, Italy). Motor
coordination behavior was analyzed using the Rota-Rod test
(Mouse Rota-Rod; Ugo Basile). Paw thickness was measured
using a thickness gauge (Model No. 7313; Mitutoyo Corporation,
Kawasaki, Japan). Body weight was recorded before and at the
end of the experiments. For determination of general activity and
explorative behavior, an open-field experiment was performed.
The mice were put in the open-field arena (50 3 50 cm, gray
plastic), and their activity was determined by a video tracking
system (VideoMot; TSESystems, BadHomberg, Germany) for 15
minutes. Total distance and regional preference were
determined.
2.4. High-pressure liquid chromatography
To investigate the concentrations of glycine and EG using high-
pressure liquid chromatography (HPLC), EG (200 mg/kg) was
injected subcutaneously in adult male Wistar rats (n5 24). Blood
and cerebrospinal fluid (CSF) samples were taken before, 1, 2, 4,
6, and 24 hours after application (n 5 6 each group). Blood
samples (#5 mL) were collected by percutaneous cardiac
puncture under deep general anesthesia using isoflurane. Sub-
sequently, CSF samples (#100 mL) were drawn from the cisterna
magna as previously described.40 After collection of whole blood,
samples were allowed to clot for 30 minutes at RT and
subsequently centrifuged at 2000g for 10 minutes at 4˚C in order
to carefully acquire the serum as the supernatant. All samples
were stored at 220˚C before analysis. For calibration, 5
concentrations of glycine and N-ethylglycine (10, 50, 100, 500,
and 1000 mM) were prepared in water. Protein-free extracts were
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prepared by mixing a sample volume of 100 mL with 900 mL
methanol containing 20 mM norleucine as internal standard. After
centrifugation, methanol was removed from the supernatants
using a vacuum evaporation centrifuge for 3 hours at room
temperature. Subsequently, 20 mL drying solution containing
methanol/1 M sodium acetate/triethylamine (2/2/1 by vol) was
added to each sample before lyophilization overnight. Then,
samples were treated for 20 minutes at room temperature with
40 mL of a derivatizing buffer containing methanol/triethylamine/
phenyl isothiocyanate/water (7/1/1/1 by vol) and lyophilized again
overnight. Samples were then dissolved in 100 mL methanol and
analyzed using a 1503 4.6 mmC18 Hypersil column (Synergi 4u
Hydro-RP 80A; Phenomenex; Macclesfield, United Kingdom) on
an analytical HPLC system (Shimadzu Instruments, Columbia,
MD) with ultraviolet detection at 254 nm.
2.5. Spinal cord electrophysiology
Electrophysiological recordings were performed on adult male
Wistar rats as previously described.13 General anesthesia was
induced in a chamber using 3.0% (vol/vol) isoflurane in 66% (vol/
vol) N2O and 33% (vol/vol) O2 and was thereafter maintained at
0.7% (vol/vol) isoflurane in 66% (vol/vol) N2O and 33% (vol/vol)
O2. Core body temperature was monitored and maintained at
37˚C by a homeothermic heating blanket unit and rectal probe.
Laminectomywasperformed to expose theL4andL5segments of
the spinal cord. Using a parylene-coated tungsten electrode (A-M
Systems, Carlsborg, WA), neurons in deep laminae (;500-1000
mm from the dorsal surface of the cord) receiving afferent A-fiber
and C-fiber input from the hind paw were sought by periodic light
tapping of the glabrous surface of the hind paw. Extracellular
recordings made from single neurons were visualized on an
oscilloscope and discriminated on a spike amplitude and
waveformbasis. Electrical stimulationwas given through 2 needles
inserted into the receptive field, and a train of 16 stimuli was given (2
milliseconds pulse duration, 0.5 Hz at 3 times the C-fiber
threshold). Responses evoked by Ab, Ad, and C fibers were
superimposed and separated according to latency (0-20, 20-90,
and 90-350 milliseconds, respectively). A range of natural
stimuli, including brush, von Frey filaments (8 and 60g), and
heat (40˚C and 48˚C constant water jet), were applied to the
receptive field for 10 seconds per stimulus, and the evoked
neuronal firing was quantified. Data were captured and
analyzed by a CED 1401 interface coupled to a personal
computer with Spike2 software (Cambridge Electronic De-
sign). Stabilization of a neuron’s responses to the range of
electrical and natural stimuli was confirmed with at least 3
consistent responses (,10%) to all measures. Mean values of
these responses were calculated and used as pretreatment
controls. Carrageenan (1%, 20 mL) was subsequently injected
into the left hind paw to induce an inflammatory response.
Evoked responses were recorded at intervals of 20 minutes
until hyperexcitability had fully developed at 3 hours after
application of carrageenan. Then, EG at concentrations of 10,
30, 100, and 1000 mM was administered onto the dorsal
surface of the spinal cord followed by further recordings at 30
minutes after application.
2.6. Statistical analysis
Data are expressed as mean6 SEM. Differences in mean values
were tested by 1- or 2-way analysis of variance, with Bonferroni
post hoc test where appropriate. Calculations were performed
using the GraphPad Prism software version 5.0 (GraphPad
Software Inc, La Jolla, CA). Results from behavioral observation
regarding neurological side effects were analyzed with the
Mantel–Cox log-rank test. P , 0.05 was considered significant.
3. Results
3.1. The lidocaine metabolite EG specifically acts as
a substrate for GlyT1
To determine whether the lidocaine metabolite EG acts
specifically on GlyT1 or, like sarcosine, also on other key
components of the glycinergic system,52,53 we expressed
GlyT1, GlyT2, the glycine receptor subunits GlyR a1, a2, and
a3, or the NMDAR (NR1/NR2a) in X laevis oocytes. Here,
application of increasing concentrations of glycine to the
respective GlyT-expressing oocytes resulted in a typical
concentration-dependent current response (Fig. 1 and
Fig. 2), in line with an electrogenic glycine uptake through both
transporters. Consistent with previous studies, we also
obtained concentration-dependent currents when GlyT1-
expressing oocytes were superfused with sarcosine or EG
(Ref. 46; see also Fig. 1). In contrast, no sarcosine- or EG-
induced currents were observed in GlyT2-expressing oocytes
(Fig. 1). Furthermore, simultaneous application of glycine (20-
2000mM) and EG (2000mM) ontoGlyT2-expressing oocytes did
not result in any significant change in the current amplitude as
compared with the application of glycine alone (Fig. 1C). These
findings clearly indicate that EG is neither an alternative
substrate nor a partial inhibitor of GlyT2.
Similarly, no EG-induced currents were observed in recordings
from oocytes expressing GlyR a1, a2, or a3 homopentameric
receptors, although glycine and even sarcosine-induced currents
were readily detectable (Fig. 2A, B, D-F). To analyze whether EG
acts as a (partial) antagonist on the glycine receptor, glycine and
EG were coapplied to oocytes expressing the respective
homopentameric receptor. Here, in none of the recordings,
significant effects of EG coapplication on the current amplitude as
compared with the currents observed after application of glycine
alone were observed, demonstrating that EG does not function
as a partial antagonist concerning any of these proteins (Fig. 2G-
I). At central nervous system (CNS) synapses, the majority of
GlyRs is not present as GlyR a homopentameric receptors but as
heteropentamers together with the GlyR b.21 To exclude that EG
acts specifically on these heteropentameric receptors, the effects
of EG and/or sarcosine were also analyzed in oocytes expressing
the respective heteromers. Here, no significant differences to
oocytes expressing the respective GlyR a homoreceptor were
observed (Fig. 2C-I), confirming that EG acts neither in an
agonistic nor antagonistic fashion on GlyRs.
Similar to our experiments on GlyT2 and GlyR receptors,
effects of EG on NMDAR (NR1/NR2a) currents were analyzed
(Fig. 3). Although NMDAR-mediated currents were readily
detectable after application of glycine together with glutamate
(Fig. 3A-C, E), no substance-induced currents were observed
when glutamate or glycine was applied alone. Application of EG
either alone, or in combination with glycine or glutamate, did not
produce significant substance-induced currents (Fig. 3A, D). To
determine whether EG inhibits NMDAR-mediated currents in-
duced by glutamate and glycine, all 3 substanceswere applied on
NMDAR-expressing oocytes. Similar to our observations in
GlyT2- and GlyR-expressing oocytes, the observed current
amplitude after application of all 3 substances was indistinguish-
able from that observed after the application of glutamate and
glycine alone (Fig. 3E), indicating that EG does not function as an
inhibitor at the NMDAR.
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The application of any of the aforementioned substances had
no effect on currents in noninjected (wild-type) oocytes (data not
shown). Taken together, these data show that EG acts only as
a substrate for GlyT1 but has no agonistic or antagonistic function
at the other major glycine-responsive proteins within the CNS.
3.2. Systemic application of EG efficiently ameliorates
inflammatory hyperalgesia
To test whether the lidocaine metabolite EG can directly exert an
antinociceptive effect on inflammatory pain in vivo, CFA was
injected into the left hind paw of adult male C57BL/6Jmice (n5 8
per group). Testing of mechanical sensitivity using von Frey
filaments revealed a profound allodynia that developed in the
treated paw 72 hours after injection of CFA, whereas mechanical
sensitivity of the untreated paw was not altered. Subcutaneous
bolus application of EG (200 mg/kg) or sarcosine (200 mg/kg)
increased withdrawal thresholds observed in the CFA-treated
paw within 1 hour after application, indicating a reduction of
mechanical hyperalgesia. After a plateau of 4 hours, the apparent
beneficial effect of EG and sarcosine slowly declined, and after 24
hours, the mechanical sensitivity was back to baseline levels
(Fig. 4A). In contrast, mechanical sensitivity of the untreated
contralateral hind paw did not change at any point during the
experiment (Fig. 4B). The antihyperalgesic effect was fully
reproducible when repeating the treatment after 48 hours
(Fig. 4A). When repeating EG applications at 12-hour intervals
for 3 consecutive days, however, no additional beneficial effects
in the sense of a delayed therapeutic response were observed
when evaluating 12 hours after injection (data not shown).
To test whether this antihyperalgesic effect results from an
anti-inflammatory effect of EG or sarcosine, the degree of
inflammation-induced edema was determined on the basis of
paw thickness. Here, thickness of the paw that received the
CFA injection (left paw) was approximately 40% increased as
compared with the untreated control side, confirming, in
addition to the behavioral data, the successful induction of
the inflammation. At 24 hours after treatment with sarcosine or
EG, however, no change in the inflammation-induced edema
was observed, suggesting that, at least in the current
experimental setting, neither test drug shows any anti-
inflammatory potential (Fig. 4C).
To determine the dose dependency of EG in this model of
inflammatory pain, inflammation-induced hyperalgesia was
induced by CFA injection in the left hind paw of the animals.
After successful verification that a pronounced allodynia had
developed, various concentrations of EG were injected sub-
cutaneously and the withdrawal threshold after mechanical
stimulation tested 2 hours after injection (n 5 8 per group).
Half-logarithmic plotting of the data revealed an EC50 of
98 mg/kg (Fig. 5A).
To test for possible side effects of EG that might result from
a general increase of the glycinergic tone or from other routes of
action, eg, acute toxic effects, the general activity of mice after
treatment with 400 mg/kg EG was analyzed and compared with
mice injected with 40 mg/kg of the parent substance lidocaine
(n 5 8 per group). Although in all lidocaine-treated animals,
severe adverse effects like irregular movements or (respiratory)
distress were seen within the first 8 minutes after injection, such
effects were not observed in any of the mice treated with the
lidocaine metabolite EG (Fig. 5B). To determine whether EG
treatment causes subtle adverse effects, that result from, for
example, a general increase in the glycinergic tone, the motor
performance of mice was analyzed with rotarod assay before
Figure 1. N-ethylglycine (EG) is an artificial substrate for glycine transporter 1
(GlyT1) but has no effect on glycine transporter 2 (GlyT2) function. Xenopus
laevis oocytes were injected with complementary RNA encoding for mouse
GlyT1 or GlyT2. Substance-induced currents were recorded at a membrane
potential held at 250 mV. The respective substances were applied for 20
seconds each followed by a washout of 30 seconds. (A), Representative
substance-induced currents for 30 mM glycine (Gly), 1 mM sarcosine (Sar), 1
mM EG, and Gly/EG coapplication were recorded from oocytes expressing
GlyT1 or GlyT2, respectively. (B), Average amplitude of the substance-induced
currents (EG or sarcosine in the respective concentration) in recordings from
GlyT1- or GlyT2-expressing oocytes in relation to the maximal glycine-induced
current. Note that EG and sarcosine did not induce currents in GlyT2-
expressing oocytes, while glycine led to robust GlyT2-mediated currents. Data
are expressed as mean 6 SEM (n 5 4-6). (C), Comparison of substance-
induced currents recorded fromGlyT2-expressing oocytes induced by glycine
at indicated concentrations or after coapplication of glycine and EG at
indicated concentrations. EG did not alter the glycine-induced currents. Data
are expressed as mean 6 SEM (n 5 4-6).
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and 2 hours after EG treatment and compared with that of
sarcosine- or saline-treated animals (Fig. 5C; n5 8 per group).
Both, before and after EG treatment, the performance of the
animals in all 3 groups was indistinguishable, suggesting that
short-term treatment with EG does not produce major side
effects in mice. Consistent with these findings, no change in
the paw withdrawal threshold to heat exposure using the
Hargreaves test was observed after application of EG to naive
animals at any time point analyzed (Fig. 5D; n 5 8 per group),
indicating that responses to acute painful stimuli were not
Figure 2. N-ethylglycine (EG) does not induce significant glycine receptor (GlyR)–mediated currents in Xenopus laevis oocytes. Xenopus laevis oocytes were
injected with complementary RNA encoding for mouse GlyR a1, GlyR a2, or GlyR a3 alone or coinjected with complementary RNA encoding for GlyR b.
Substance-induced currents were recorded with themembrane potential held at250mV. The respective substances were applied for 15 seconds each followed
by a washout of 30 seconds. (A), Representative substance-induced currents for 200 mM glycine (Gly), 1 mM sarcosine (Sar), and 1 mM EG were recorded from
oocytes expressing the indicated GlyR subunit. (B and C), Concentration/response curve of currents elicited by glycine normalized to maximal glycine inducible
currents as determined on oocytes expressing GlyR a1, GlyR a2, or GlyR a3 (depicted in B) or GlyR a1/b, GlyR a2/b, or GlyR a3/b (depicted in C), respectively.
Data are expressed as mean 6 SEM (n 5 4-6). (D-F), Oocytes expressing GlyR a1 (D), GlyR a2 (E), or GlyR a3 (F) or the respective heteropentameric GlyR a/b
receptors were superfusedwith EG- or sarcosine-containing solutions. Substance-induced currentswere given in relation to themaximal glycine-induced current.
Note that although small sarcosine-induced currents were observed in recordings from oocytes expressing any of the GlyR subunits, no or negligible EG-induced
currents were observed. Data are expressed as mean6 SEM (n5 4-6). (G-I), Oocytes expressing the respective GlyR subunit (GlyR a1 in [G], GlyR a2 in [H], or
GlyR a3 in [I], depicted with open circles) or the respective heteropentameric GlyR a/b receptors (depicted as filled circles) were superfused with glycine at the
indicated concentration alone or in combination with 2mMEG. Currents were determined as fraction of the current elicited by glycine alone. Data are expressed as
mean 6 SEM (n 5 4-6).
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altered after EG treatment. The effect of EG application on
general activity and explorative behavior was subsequently
determined in an open-field experiment. Here, neither the
general activity of EG-treated mice (200 mg/kg, subcutane-
ously) as determined by the total distance traveled nor their
explorative behavior as determined by the regional preference
for the central quadrant was distinguishable from that of mice
that received saline injections only (Fig. 5E-G; n 5 6-7 per
group). Taken together, these data demonstrate that systemic
application of EG, similar to sarcosine, efficiently ameliorates
inflammatory hyperalgesia, whereas acute pain sensitivity is
not affected. Moreover, these data reveal no major
additional effects of acute EG treatment on the general activity
of mice.
3.3. Systemic application of EG reduces allodynia and
hyperalgesia in mice with neuropathic pain
Subsequently, we analyzed whether EG has an antinociceptive
effect only in inflammatory pain or whether this phenomenon can
also be observed in an animal model of neuropathic pain. To
induce neuropathy, we made use of the CCI model of the sciatic
nerve. The establishment of CCI-induced allodynia and hyper-
algesia was determined by mechanical and thermal testing of
withdrawal thresholds. All animals analyzed (n 5 8 per group)
developed pronounced mechanical allodynia and thermal hyper-
algesia within 72 hours after the operation at the ipsilateral side
(Fig. 6), whereas no changes in pain sensitivity were observed at
the contralateral side (data not shown). Upon subcutaneous
injection of EG, a significant reduction of both CCI-induced
Figure 3.N-ethylglycine (EG) does not influenceNMDAR-mediated currents in Xenopus laevis oocytes.Xenopus laevis oocyteswere injectedwith complementary
RNA encoding for mouse. Substance-induced currents were recorded with the membrane potential held at250mV. The respective substances were applied for
15 seconds each followed by a washout of 30 seconds. (A), Representative substance-induced currents for 1mMglutamate (Glu), 2mMglycine (Gly), 100mMEG,
or the indicated coapplications EG were recorded from oocytes expressing the NMDAR (NR1/NR2a). (B), Concentration/response curve of currents elicited by
glutamate in the presence of saturating concentrations of glycine (100 mM) normalized to maximal glutamate inducible currents as determined on oocytes
expressing the NMDAR (NR1/NR2a). Data are expressed as mean 6 SEM (n 5 4-6). (C), Concentration/response curve of currents elicited by glycine in the
presence of saturating concentrations of glutamate (100 mM) normalized to maximal glycine inducible currents as determined on oocytes expressing the NMDAR
(NR1/NR2a). Data are expressed asmean6 SEM (n5 4-6). (D), Oocytes expressing NMDAR superfused with EG at the indicated concentrations in the presence
of saturating concentrations of glutamate (100 mM). Substance-induced currents were given in relation to the maximal glycine-induced current (determined after
superfusion with 100 mM glutamate and 100 mM glycine). Data are expressed as mean6 SEM (n5 4-6). (E), Oocytes expressing the NMDAR (NR1/NR2a) were
superfused with glutamate, glycine, or EG at the indicated concentration alone or in the indicated combinations. Currents were determined as fraction of the
current elicited by glycine and glutamate (100 mM each) alone. Data are expressed as mean 6 SEM (n 5 4-6).
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mechanical (Fig. 6A) and thermal hyperalgesia (Fig. 6B) was
observed within 2 hours after injection. Similar to our findings for
inflammatory pain, the observed reduction in hyperalgesia was
only transient with a maximal effect observed after 2 to 4 hours.
Pain sensitivity was indistinguishable from that of saline-treated
mice at 24 hours after injection (Fig. 6).
3.4. Systemic application of EG leads to an increase in serum
and cerebrospinal fluid glycine concentrations
Based on its action on GlyT1 as an artificial substrate, we
hypothesized that EG might compete with glycine for the uptake
into the surrounding tissue of glycinergic synapses and thus
cause an increase in the extracellular glycine concentration at
least within the CNS. Therefore, we investigated both the
concentration of EG and glycine in the serum and CSF in EG-
treated animals. As the obtained volume, especially of CSF, was
not sufficient for HPLC-based analysis when isolated from mice,
we performed these experiments in rats (n5 4 per group). In the
serum of untreated rats, a basal glycine concentration of 207 6
37 mM was observed. Interestingly, EG also was already found
in low concentrations (43 6 6 mM). After subcutaneous injection
of EG, a rapid increase in the EG serum concentration was
observed that peaked with 384 6 34 mM only 1 hour after
injection. After a 1-hour plateau, a steady decline of the serum EG
concentration was observed, and after 24 hours, the serum
concentration of EG reached the basal level. During the whole
observation period, however, there was no significant change in
the serum glycine concentration (Fig. 7A). Based on these
measurements, we calculated a volume of distribution for EG of
approximately 1.2 L or 4.8 L/kg. Thus, a theoretical dose of 98
mg/kg, estimated as EC50 in our behavioral dose–response
experiments (Fig. 5A), would result in a serum concentration of
20.4 mg/L (198 mM) 2 hours after injection.
In contrast to our findings on the serum concentrations of EG
and glycine, much lower basal concentrations were found in
CSF samples of untreated animals (16.5 6 0.5 mM and 5.5 6
0.9 mM for glycine and EG, respectively). In samples from
animals that received EG injections, the concentration of EG
almost doubled within 2 hours after injection, followed by a slow
decline. Corroborating our serum concentration findings, the
EGCSF levels of rats that received EG injections 24 hours before
testing were indistinguishable from those of untreated control
animals. Analysis of the CSF glycine concentration revealed that
EG injection resulted in a 25% increase in extracellular glycine
concentration (to 20.5 6 1.9 mM). The maximal increase was
observed 2 hours after injection of EG. Subsequently, the CSF
glycine concentration slowly declined and in rats that received
the EG injection 24 hours before CSF sampling, glycine
concentrations were comparable with those of untreated
animals (Fig. 7B).
Taken together, these findings demonstrate that after systemic
application, EG reaches the CSF and has an effect on the
extracellular glycine concentration that is consistent with a tran-
sient reduction of the GlyT1-mediated glycine transport capacity.
3.5. EG affects the pain processing circuitry by inhibiting the
inflammation-induced hyperexcitability of dorsal
horn neurons
To investigate the effects of EG on the evoked responses of
dorsal horn neurons, we determined the number of action
potentials elicited by electrical stimulation in recordings from
WDR neurons of the deep laminae in the rat spinal cord dorsal
horn. After recording baseline responses after stimulation of the
corresponding receptive field at the glabrous surface of the
hind paw, an inflammatory response followed by neuronal
hyperexcitability was induced by injection of 1% carrageenan
Figure 4. N-ethylglycine (EG) reduces nociceptive behavior in inflammatory
pain. (A), Behavioral data in adult mice after induction of inflammatory pain by
injection of complete Freund’s adjuvant (5mL) in the left hind paw expressed as
50% withdrawal threshold (in g). EG (200 mg/kg), the known GlyT1 substrate
sarcosine (Sar, 200 mg/kg), or saline was applied subcutaneously after
allodynia had developed 3 days after induction (marked with arrow).
Assessment of mechanical allodynia was performed with von Frey hairs at
indicated time points. Please note that the treatment was repeated at 48 hours
after initial treatment (marked with arrow) to test whether the effects can be
achieved again. Data are expressed as mean 6 SEM; n 5 8 per group; *P ,
0.05 vs control group (saline); 2-way repeated-measures analysis of variance
and Bonferroni post hoc test. (B), Corresponding data from complete Freund’s
adjuvant–untreated right hind paws. (C), Inflammatory edema was assessed
by means of paw thickness (mm) 24 hours after first treatment with EG. Data
are expressed as mean 6 SEM; n 5 8 per group; no significant differences
were detected between treatment groups; 1-way repeated-measures analysis
of variance and Bonferroni post hoc test.
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solution into the hind paw. Individual action potentials were
attributed to the respective fiber types according to their
latency (Ab fibers: 0-20 milliseconds, Ad fibers: 20-90 milli-
seconds, and C fibers: 90-350 milliseconds). Here, evaluation
of electrical stimulus–evoked responses revealed that the
majority of detected action potentials had a stimulus–response
latency that corresponded to C fibers (90-350 milliseconds),
while neuronal input from Ab and Ad fibers was less abundant
(see Fig. 8A and Supplemental Digital Content 1 [available
online at http://links.lww.com/PAIN/A93], which contains
examples of responses of single neurons to electrical stimula-
tion at baseline, after carrageenan injection and subsequent EG
treatment). After carrageenan injection, a significant increase in
the firing rate in response to Ab-, Ad-, and C-fiber activity was
observed after 3 hours. Subsequently, EG was applied directly
onto the dorsal surface of the spinal cord (n 5 4 per group).
Further recordings 30 minutes after application revealed
a dose-dependent reduction of detected action potentials in
Figure 5. Dose–response relationship of N-ethylglycine (EG) for treatment of inflammatory pain and screening for secondary and acute analgesic effects. (A),
Dose–response for the effect of EG on thermal hyperalgesia (withdrawal thresholds using the Hargreaves method) 3 days after the induction of inflammatory pain
by complete Freund’s adjuvant (5 mL) injection. Data are expressed as mean6 SEM; n5 8 per group. (B), High-dose treatment with EG does not induce adverse
neurological side effects; time until occurrence of signs of adverse effects was recorded in adult naive mice after subcutaneous injection of lidocaine (40 mg/kg) or
EG (400 mg/kg). Data are expressed as the fraction (in %) of symptom-free animals (no irregular movements or signs of distress); n5 8 per group; ***P, 0.001
between groups; Mantel–Cox log-rank test. (C), EG (200 mg/kg), the known GlyT1 substrate sarcosine (Sar, 200 mg/kg), or saline was applied subcutaneously in
adult mice after allodynia had developed 3 days after induction. Motor coordination was tested using the rotarod performance test before and 2 hours after
treatment with EG. Riding times (in seconds) were measured. Data are expressed as mean 6 SEM; n 5 8 per group; no significant differences were detected
between treatment groups; 1-way repeated-measures analysis of variance andBonferroni post hoc test. (D), Behavioral data in naive adult mice in the left hind paw
expressed as pawwithdrawal threshold (in seconds) after subcutaneous application of EG (200mg/kg), sarcosine (200mg/kg), or saline. Assessment of analgesic
effects was performed using the Hargreaves method at indicated time points. Data are expressed as mean6 SEM; n5 8 per group; no significant differences vs
control group (saline) were detected; 2-way repeated-measures analysis of variance and Bonferroni post hoc test. (E-G), Open-field experiments were performed
2 hours after receiving a single dose of EG (200 mg/kg, subcutaneously). Total distance (E) and the time spent in the periphery (F) or the central quadrant (G) were
determined. Data are expressed as mean6 SEM, n5 6 to 7 per group; no significant differences vs control group (saline) were detected (Student t test, P. 0.6).
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response to electrical stimulation reaching complete suppres-
sion of neuronal hyperexcitability at concentrations higher than
100 mM (Fig. 8B). As individual neuron responses varied
considerably, normalization to maximal responses (3 hours
after carrageenan injection) was performed. To determine
whether this dose-dependent reduction in the firing rate of
dorsal horn neurons was also observed in reaction to
physiological stimuli, the respective receptive field at the
glabrous surface of the hind paw was stimulated thermally
(Fig. 8C; constant water jet 40˚C or 48˚C) or mechanically (Fig.
8D; brush, 8 or 60g hair). Here, consistent with our findings
after electrical stimulation, we observed a strong facilitation of
the stimulus-induced firing rate after carrageenan with in-
nocuous stimuli being affected more strongly. After treatment
with increasing concentrations of EG, the carrageenan-
induced hyperexcitability was dose-dependently reduced.
Here, also a stronger effect was observed, when normally
innocuous stimuli (8g hair, 40˚C water jet) were applied. These
findings demonstrate that EG affects the pain processing
circuitry by inhibiting the inflammation-induced hyperexcitabil-
ity of dorsal horn neurons, thus confirming the antihyperalgesic
action of EG independently of behavioral approaches.
4. Discussion
Treatment of chronic pain is still one of the most challenging
clinical endeavors. Here, classical analgesics like opioids and
nonsteroidal antirheumatics usually have limited efficacy. Despite
continuing research, no substantial improvement in therapeutic
outcome has emerged.4,29
For more than 50 years, it has been known that systemic long-
term application of lidocaine results in a long-lasting general
antinociceptive effect,33 although the mechanism mediating
these effects remained up to now enigmatic. The relative late
onset of the therapeutic benefit, as well as the extremely low
levels of the plasma lidocaine concentration required, argue
against a direct function of lidocaine on the principal target of this
class of substances ie, voltage-gated sodium channels.47 Pre-
vious studies have demonstrated that in addition to the general
analgesic effect, long-term treatment with lidocaine has an anti-
inflammatory potential31 through an up-to-now unknown mech-
anism, which might contribute to the long-lasting beneficial
effects. In this study, we provide evidence that the antinociceptive
effect seen after long-term treatment with lidocaine can be
mimicked by systemic application of the lidocaine metabolite EG,
which acts as an artificial substrate specifically on glycine
transporters of the GlyT1 subtype, suggesting a novel additional
route of action for systemically applied lidocaine. Systemic
application of EG results in a significant elevation of the
Figure 6. N-ethylglycine (EG) reduces nociceptive behavior in neuropathic
pain. (A), Behavioral data in adult mice after induction of neuropathic pain by
chronic constriction injury in the left hind paw expressed as 50% withdrawal
threshold (in g). EG (200 mg/kg) or saline was applied subcutaneously after
mechanical allodynia had developed 3 days after chronic constriction injury.
Assessment of mechanical allodynia was performed with von Frey filaments at
indicated time points. (B), Thermal hyperalgesia was assessed by means of
pawwithdrawal thresholds (in seconds) in response to a heat source applied to
the left hind paw (Hargreaves method). Data are expressed as mean 6 SEM;
n 5 8 per group; *P , 0.05 vs control group (saline); 2-way repeated-
measures analysis of variance and Bonferroni post hoc test.
Figure 7. Subcutaneous injection of N-ethylglycine (EG) in rats leads to an
increased EG concentration in blood serum and to increased EG and glycine
(Gly) concentrations in cerebrospinal fluid. Concentrations of EG and glycine
were determined using high-pressure liquid chromatography in (A) blood
serum and (B) cerebrospinal fluid samples from adult rats before and at
indicated time points after subcutaneous injection of EG (200mg/kg). Data are
expressed as mean6 SEM; n5 4 per group; *P, 0.05 vs before injection of
EG; 1-way analysis of variance and Bonferroni post hoc test.
September 2015·Volume 156·Number 9 www.painjournalonline.com 1655
Figure 8. N-ethylglycine (EG) reduces wide-dynamic-range neuron response in inflammatory pain. Action potentials of single neurons in response to electrical
stimulation (A/B), thermal stimulation (C) or mechanical stimulation (D) of the receptive field were recorded. Responses evoked by Ab, Ad, and C fibers after
electrical stimuli were superimposed and separated according to latency (0-20, 20-90, and 90-350 milliseconds, respectively). Representative data from one
individual neuron recording (A) demonstrating that themajority of action potentials are elicited by C-fiber input after electrical stimulation. (B-D), Relative number of
action potentials elicited by the indicated fiber inputs, with the respective number recorded after carrageenan treatment set to 100%. Thermal stimuli were applied
by means of a constant water jet at 40˚C and 48˚C. Mechanical stimuli were applied with a fine brush or von Frey hairs (8 and 60g force). Inflammatory pain was
induced in adult rats by injection of carrageenan (1%, 20 mL) at the left hind paw. EG was applied intrathecally after hyperexcitability had developed 3 hours after
carrageenan application. Effect of EG on neuronal response to stimuli was tested 30 minutes after application. (B-D), Data are expressed as mean6 SEM; n5 8
for controls and n5 4 for each concentration of EG; *P, 0.05, **P, 0.01 and ***P, 0.001 vs neuronal response after carrageenan application; 1-way repeated-
measures analysis of variance and Bonferroni post hoc test.
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extracellular glycine concentration within the CSF and thereby
inhibition of inflammation-induced hyperexcitability of WDR
neurons in the deep lamina of the dorsal horn.
In the mature nervous system, the extracellular glycine
concentration is synergistically regulated by GlyT1 and GlyT215
withGlyT2 being essential for replenishing the presynaptic glycine
pool. Loss of the GlyT2 activity results in a pronounced
disinhibition of motor neurons and consequently leads to severe
neuromotor deficits in both rodents and humans.16,20,38 In
contrast, the major function of glial GlyT1 is the maintenance of
low extracellular glycine concentrations.19 Inactivation of GlyT1
expression in glial cells of neonatal animals results in severe
hypotonia, respiratory depression and premature death. At later
developmental stages, however, a loss of glial GlyT1 seems to be
well tolerated.17 Additionally, neuronal expression of GlyT1 has
been shown to be an important modulator of glutamatergic
neurotransmission through glutamate receptors of the NMDAR
subtype.50 Therefore, GlyT1 inhibitors are currently in phase 3
trials for the treatments of diseases associated with NMDAR
dysfunction like schizophrenia (see, eg, ClinicalTrials.gov Identi-
fier: NCT01192867).
There is an increasing body of evidence, in addition to this
study, that suggests both inhibition of GlyT1 and GlyT2 are
suitable strategies for the treatment of chronic pain conditions
including inflammatory and neuropathic pain.25 The interpretation
of these findings has in many cases been hampered by the fact
that the currently available inhibitors are poorly characterized
and/or are proven to cross-react with other components of
glycine-dependent neurotransmission. For example, the GlyT2
inhibitor ALX1393 also inhibits GlyT1 at low micromolar concen-
trations,34 while the GlyT1 substrate sarcosine was shown to act
also as a partial agonist on GlyR53 and NMDAR.52 In contrast, we
found EG to be specific for GlyT1 without any effects on GlyT2,
GlyRs, or NMDARs in vitro. This high specificity for GlyT1 might
facilitate better predictability of the expected effects in vivo and
therefore prevent undesired secondary effects.
Our behavioral experiments show that systemic EG is dose-
dependently antinociceptive in chronic but not acute pain.
Interestingly, EG diminished pain states induced by either
inflammation or CCI in the same manner, although the spinal
cord pathophysiology has been shown to be different. In contrast
to neuropathic pain,26,28 inflammation-induced pain requires an
increase in the production of the pronociceptive prostaglandin
PGE2 in the spinal cord, which diminishes glycinergic inhibition in
the dorsal horn by phosphorylation of a3 subunit containing
GlyR.1,24 Thus, it appears that the reduction of the glycine uptake
capacity of GlyT1 might constitute a general treatment strategy
for diseases associated with a diminished inhibitory neurotrans-
mission in caudal regions of the CNS like chronic pain with central
sensitization.
The time course of the antinociceptive effect elicited by EGwas
similar in CFA- and CCI-induced pain; withdrawal thresholds
were already significantly increased within 1 hour after applica-
tion, and this increase lasted for 4 to 6 hours. Thus, onset of
antinociceptive effects was significantly faster than what was
observed with GlyT1 inhibitors previously.5,35 Whether this
discrepancy in the kinetics of action results from differences in
the pharmacokinetics or from a different mechanism (eg, inhibitor
vs artificial substrate) is not clear at present.
Measurements of serum concentrations revealed that after
subcutaneous injection, serum EG concentrations increased
quickly and remained elevated for 2 hours at levels slightly below
400 mM while serum glycine concentration remained un-
changed. These findings support the idea that EG specifically
acts on GlyT1 because the plasma concentration of glycine has
been suggested to be controlled by other (low affinity) trans-
porters such as System A.32 Interestingly, EG concentrations
found after subcutaneous EG injection were similar to those
reported in the plasma of patients receiving continuous
systemic or epidural applications of lidocaine (range: 3-65
mg/L, ie, 30-650 mM).39 By measuring the spinal fluid EG and
glycine levels, we could show that EG crosses the blood–brain
barrier and leads to a short-term increase in spinal fluid glycine
concentration. This further supports the hypothesis that EG
functions through a reduction of the glycine transport capacity
of GlyT1. It has to be noted, however, that the concentration
measurements performed here only allow for an evaluation of
extrasynaptic glycine levels that may differ from those at
synaptic sites. Taken together, these data suggest that after
continuous application of lidocaine, EG can accumulate and
reach plasma concentrations that are sufficient for a significant
glycine transport inhibition in vitro and antinociceptive effects in
vivo. These results strongly suggest that the antinociceptive
effects of systemic lidocaine are caused by EG accumulation
that results in elevated glycine levels at synapses of spinal
inhibitory circuits.
In previous studies, the beneficial effect of GlyT inhibitors was
observed only when a fraction of the total GlyT activity was
blocked. Strong inhibition of GlyT1 activity caused severe
adverse effects like pronociceptive effects, neuromotor dis-
turbances, or respiratory depression.27,35,37 Such negative
consequences were not observed in animals treated with even
twice the antinociceptive dose of EG. This possibly could be
explained by EG’s only moderate affinity for GlyT1 and the fact
that EG, in contrast to previously evaluated substances,
constitutes an artificial GlyT1 substrate and does not act as an
inhibitor of GlyT1.
Interestingly, previous studies have shown that long-term
blockade of GlyT1 by the irreversible GlyT1 inhibitor ALX5407
appears not only to ameliorate pathological pain symptoms but
also to reverse some of the neuroplastic changes involved in the
manifestation of neuropathic pain such as an increase of NMDAR
subunit expression NR1 within the spinal cord.5 This might result
from the previously described internalization of NMDAR after
sustained saturation of the NMDAR glycine binding.36 These
effects might facilitate the beneficial effects of GlyT1 in the
treatment of pathological pain and explain some of the long-
lasting effects of even a single dose application of GlyT1
inhibitors.35 In this study, using the GlyT1 substrate EG, no
long-lasting antihyperalgesic effect was observed,most likely due
to the relative short treatment period and the fact that here we
used not a GlyT1 inhibitor but an artificial substrate. Whether
injection of higher doses or continuous application of EG might
result in sustained or long-lasting effects on nociception remains
to be elucidated in further experiments.
Using in vivo extracellular recordings at dorsal horn neurons in
the deep laminae of the rat lumbar spinal cord, we identified
strong inhibitory effects of EG on inflammation-induced neuronal
hyperexcitability in WDR neurons. Here, only intrathecal concen-
trations of more than 100 mM EG led to complete suppression of
neuronal hyperexcitability, although significant effects were
observed using 30 mM EG. This finding most likely results from
inhibition of glycine uptake capacity and the subsequent
accumulation of extracellular glycine. Support for the hypothesis
that this is the most likely mode of action also comes from our
HPLC experiments, which show that CSF concentrations of up to
20 mM EG can be reached by systemic application of EG at
a dose that has been shown to be effective in behavioral
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experiments (200 mg/kg). However, it has to be considered that
all in vivo electrophysiological experiments were performed under
general anesthesia and thus a direct correlation with behavioral
data is difficult.
In conclusion, our findings suggest that EG, as a substrate of
GlyT1, mediates at least in part the antinociceptive effect of
systemically applied lidocaine. Furthermore, our results demon-
strate that competitive inhibition of GlyT1 by application of GlyT1
substrates like EG is a promising strategy for the therapy of
chronic pain conditions. Future investigations are needed to
determine the precise molecular mechanisms behind the
antinociceptive action, eg, to what extent altered spinal and
supraspinal glycinergic and glutamatergic neurotransmission
contributes to this phenomenon or whether low-affinity glycine
transport by systems A, ASC, etc., is sensitive to EG. Finally,
whether these effects can be confirmed in clinical studies remains
to be elucidated.
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